Details

Autor(en) / Beteiligte

• Shi, X.
• Cheng, Q.
• Zhao, Y.-Z.
• Zou, S.-P.
• Sun, M.-H.

Titel

A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)

Ist Teil von

• Osteoporosis international, 2023-12, Vol.34 (12), p.2047-2058

Ort / Verlag

London: Springer London

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Summary Abaloparatide (ABL) is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. However, real-world data regarding its long-term safety and tolerability in large sample population are incomplete. We evaluated abaloparatide-associated safety signals by data mining of the FDA pharmacovigilance database. Introduction We investigated 33,480(0.14%) ABL-related adverse events (AEs) through data mining of Food and Drug Administration Adverse Event Reporting System (FAERS) retrospectively. Methods Reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed to quantify the signals of ABL-related AEs from 2017Quarter2 to 2022.Serious and non-serious cases were compared by Mann-Whitney U test or Chi-squared ( χ 2 ) test. Results We collected 8,470,497 reports from the FAERS database, including 11,487 reports defined ABL as the primary suspected (PS) drug. Additionally, 36.16% of the reports were submitted by healthcare professionals ( n =4154), compared to 62.26% reported by consumers ( n =7140). A total 99 signals simultaneously conforming to four algorithms were detected, among which, 35 signals were identified as unexpected signals. Such as growing pains ( n =13), waist circumference increased ( n =21), sensory disturbance ( n =103), tinnitus ( n =65), visual acuity reduced ( n =54), blood alkaline phosphatase increased ( n =61), and hair growth abnormal ( n =13). Patient age ( p < 0.001) might be associated with an increased risk of AEs severity. The most common timeframe for AE occurrence was 0–7 days. Conclusion Our study provided a deeper and broader understanding of abaloparatide’s safety profiles, which would help healthcare professionals to mitigate the risk of AEs in clinical practice, a low number of unexpected AEs supporting ongoing additional pharmacovigilance.